Metagenomi Therapeutics, Inc.

MGX Nasdaq CIK: 0001785279

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
Business Address 5959 HORTON STREET, EMERYVILLE, CA, 94608
Mailing Address 5959 HORTON STREET, EMERYVILLE, CA, 94608
Phone (510) 871-4880
Fiscal Year End 1231
EIN 813909017

Financial Overview

FY2025

-$78.06M
Net Income
$324.60M
Total Assets
$89.74M
Total Liabilities
$41.72M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report April 3, 2026 View on SEC
4 Insider stock transaction report April 3, 2026 View on SEC
4 Insider stock transaction report April 3, 2026 View on SEC
4 Insider stock transaction report March 9, 2026 View on SEC
4 Insider stock transaction report March 9, 2026 View on SEC
4 Insider stock transaction report March 9, 2026 View on SEC
8-K Current report of material events March 5, 2026 View on SEC
10-K Annual financial report March 5, 2026 View on SEC
8-K Current report of material events January 12, 2026 View on SEC
4 Insider stock transaction report December 8, 2025 View on SEC

Annual Reports

10-K March 5, 2026
  • Successfully completed its Initial Public Offering (IPO) in February 2024, listing on Nasdaq under ticker MGX, raising substantial capital.
  • Formed significant strategic partnerships with Moderna, Ionis Pharmaceuticals, AffiniT Therapeutics, and Acuitas Therapeutics to advance gene editing and delivery technologies.
View Analysis

Insider Trading

SELL 4 insiders 7 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.